Join Together spoke with Marvin D. Seppala, MD, Chief Medical Officer of the Hazelden Betty Ford Foundation, about how some treatment programs are starting to change their view of medication-assisted treatment for opioid dependence.
Increasingly, state lawmakers are recognizing the important role that naloxone, an opioid antagonist that blocks the effects of opioids in one’s body, can play in quelling the opioid crisis in the United States, and legislatures are enacting naloxone access laws at breakneck speed.
Only 25 percent of all substance abuse treatment facilities offer at least one medication to treat alcohol use disorders (AUD), a new study finds. Although four drugs have been approved by the FDA for this purpose, many patients lack access to evidence-based treatments that can potentially benefit them, the researchers say.
Giving buprenorphine to patients addicted to opioids who are treated in the emergency room is more effective than simply providing them with a referral, a new study finds. Patients given buprenorphine were less likely to need in-patient treatment at a residential facility.
Extended-release naltrexone is associated with a much lower rate of heroin relapse in men who have been released from jail, compared with released inmates addicted to heroin who are not given treatment, a new study concludes.
Two legislators are calling on the company that makes the opioid overdose antidote naloxone to lower the price of the drug nationwide. Last month, the company, Amphastar Pharmaceuticals, agreed to offer a $6 rebate per dose to agencies in New York state.
The Clinton Foundation announced Monday it has negotiated a lower price for a device that delivers the opioid overdose antidote naloxone. The device, called Evzio, will be available at a lower price to institutions that can distribute naloxone more widely, such as police departments and universities.
The price of naloxone, the heroin overdose antidote, is skyrocketing, according to police departments and public health officials across the country. In some cases, prices for the drug have increased by 50 percent or more.
Buprenorphine maintenance therapy is more effective than detoxification for patients being treated for prescription opioid dependence, a new study finds. The researchers, from Yale University, said primary care doctors do not have evidence-based guidelines to decide between the two treatments.
Many young adults who abuse prescription opioids are not prepared to deal with an overdose, a new study finds. They tend to think prescription medications are less dangerous than heroin, the researchers say.
Buprenorphine, a medication used to treat opioid addiction, is the prescription drug most commonly implicated in emergency hospitalizations of young children, according to a new study. The drug poses a danger to children who find and accidentally swallow relatives’ prescriptions, the Associated Press reports.
After the Food and Drug Administration (FDA) decided last year not to approve implantable buprenorphine to treat opioid abuse, researchers have begun a new study to address the agency’s concerns about the product, called Probuphine.
In the past two years, 17 states have passed laws increasing access to the overdose antidote naloxone, bringing the total to 24. Most of the laws allow doctors to prescribe naloxone to friends and family members of a person who abuses opioids.